Skip to main content

Aptinyx Inc. (APTX)

NASDAQ: APTX · IEX Real-Time Price · USD
2.28
+0.03 (1.33%)
After-hours:Oct 25, 2021 7:43 PM EDT
2.25
0.03 (1.35%)
At close: Oct 25, 4:00 PM
Market Cap152.36M
Revenue (ttm)1.26M
Net Income (ttm)-56.87M
Shares Out67.38M
EPS (ttm)-0.95
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume165,678
Open2.20
Previous Close2.22
Day's Range2.16 - 2.26
52-Week Range2.15 - 4.73
Beta1.36
AnalystsStrong Buy
Price Target10.29 (+357.3%)
Est. Earnings DateNov 11, 2021

About APTX

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial ...

IndustryBiotechnology
IPO DateJun 21, 2018
Employees34
Stock ExchangeNASDAQ
Ticker SymbolAPTX
Full Company Profile

Financial Performance

In 2020, Aptinyx's revenue was $1.56 million, a decrease of -57.37% compared to the previous year's $3.67 million. Losses were -$50.05 million, -12.81% less than in 2019.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for Aptinyx stock is "Strong Buy." The 12-month stock price forecast is 10.29, which is an increase of 357.33% from the latest price.

Price Target
$10.29
(357.33% upside)
Analyst Consensus: Strong Buy

News

Aptinyx to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021

EVANSTON, Ill--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today...

17 hours ago - Business Wire

Aptinyx Appoints Gilmore O'Neill, M.B., M.M.Sc., to Board of Directors

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announce...

5 days ago - Business Wire

Aptinyx to Participate in 2021 Cantor Virtual Global Healthcare Conference

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

1 month ago - Business Wire

Aptinyx Secures $50 Million Growth Capital Credit Facility from K2 HealthVentures

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

1 month ago - Business Wire

Aptinyx to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announce...

1 month ago - Business Wire

CORRECTING and REPLACING Aptinyx Reports Second Quarter 2021 Financial Results and Business Highlights

EVANSTON, Ill.--(BUSINESS WIRE)--In the Condensed Balance Sheet, last line should read: Total liabilities and stockholders' equity   $ 134,168   $ 150,606 instead of: Total liabilities and stockholders'...

2 months ago - Business Wire

Aptinyx Reports Second Quarter 2021 Financial Results and Business Highlights

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported...

2 months ago - Business Wire

Aptinyx to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announce...

2 months ago - Business Wire

Aptinyx to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announce...

2 months ago - Business Wire

Aptinyx to Participate in William Blair Biotech Focus Conference 2021

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announce...

3 months ago - Business Wire

Aptinyx Stock Looks Promising If You're Willing to Be Patient

When you're shopping for ground-floor biotech opportunities, it pays to be patient and diligent. APTX stock is looking good here.

3 months ago - InvestorPlace

Aptinyx to Participate in Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announce...

3 months ago - Business Wire

Aptinyx to Participate in Upcoming Investor Conferences

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announce...

4 months ago - Business Wire

Aptinyx Provides Updates On Mid-Stage NYX-783 Program In PTSD Patients

After a Type C meeting with the FDA, Aptinyx Inc (NASDAQ: APTX) has finalized the design of its Phase 2b program for NYX-783 in patients with post-traumatic stress disorder (PTSD). The program will cons...

4 months ago - Benzinga

Aptinyx Provides Update on NYX-783 Development Program for the Treatment of Post-Traumatic Stress Disorder

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announce...

4 months ago - Business Wire

Best Growth Penny Stocks for 2021, Are Small-Caps Worth Watching?

Top growth penny stocks to watch this year? Check these 3 out right now The post Best Growth Penny Stocks for 2021, Are Small-Caps Worth Watching?

Other symbols:BIOLXIN
4 months ago - PennyStocks

Aptinyx Reports First Quarter 2021 Financial Results and Highlights

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported...

5 months ago - Business Wire

Aptinyx Appoints Joan W. Miller, M.D.

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

5 months ago - Business Wire

Aptinyx to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

5 months ago - Business Wire

Aptinyx Presents Additional Positive Data from Phase 2 Exploratory Study of NYX-783 in PTSD at Society of Biological ...

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

5 months ago - Business Wire

Aptinyx to Participate in Upcoming Conferences

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

5 months ago - Business Wire

Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week

5 Penny Stocks To Watch For The Last Week Of April 2021 The post Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS...

Other symbols:BLRXCYCNLCTXPTN
6 months ago - PennyStocks

Aptinyx Stock Is Trading Higher After Restarting NYX-458 Study In Dementia Associated Cognitive Impairment

Aptinyx Inc (NASDAQ: APTX) has restarted patient screening in a Phase 2 study evaluating NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinson's disease and deme...

6 months ago - Benzinga

Aptinyx Recommences Phase 2 Study of NYX-458 in Patients with Cognitive Impairment Associated with Parkinson's Diseas...

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

6 months ago - Business Wire

Aptinyx Inc. (APTX) Reports Q4 Loss, Lags Revenue Estimates

Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 16.67% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research